

Notice of Annual General Meeting

Thursday 5 December 2024 at 3:30 pm CET
Holtedam 3 (Aage Louis-Hansen Auditoriet)
Humblebæk, Denmark

Lucie
User, Ostomy Care



To the shareholders of Coloplast A/S

12 November 2024

Notice of Annual General Meeting

The general meeting will be held on **Thursday, 5 December 2024, at 3:30 pm CET** at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium).

Coffee, tea, and cake will be served at the same location before the general meeting from 3:00 pm CET to 3:30 pm CET.

The general meeting, which is also transmitted via live webcast on the company's website, www.coloplast.com, will be held in Danish. The general meeting will be opened by the Chairman of the Board of Directors and will be chaired by a chairman appointed by the Board of Directors.

Agenda with complete proposals

1. Report by the Board of Directors on the activities of the company during the past financial year.
2. Presentation and approval of the audited annual report.
3. Resolution on the distribution of profit in accordance with the approved annual report.
4. Presentation and approval of the remuneration report.
5. Approval of the Board of Directors' remuneration for the current financial year.

The Board of Directors proposes that the general meeting approves the following remuneration to the members of the Board of Directors for the financial year 2024/25:

- Members of the Board of Directors: DKK 500,000.
- Chairman of the Board of Directors: DKK 1,500,000 (equivalent to 3x base fee).
- Deputy Chairman of the Board of Directors: DKK 875,000 (equivalent to 1.75x base fee).

The Board of Directors has established an Audit Committee and a Remuneration and Nomination Committee. For the financial year 2024/25, the Board of Directors proposes the following fee to committee members for the additional duties associated with the committee work:

- A fee to each member of the Audit Committee of DKK 300,000 and a fee to the chairman of the Audit Committee of DKK 500,000.
- A fee to each member of the Remuneration and Nomination Committee of DKK 200,000 and a fee to the chairman of the Remuneration and Nomination Committee of DKK 300,000.

In addition, the members of the Board of Directors are entitled to be reimbursed for certain expenses etc. as described in the company's remuneration policy.

6. Proposals from the Board of Directors or shareholders.

No proposals have been submitted by the Board of Directors or by any shareholders for consideration under this agenda item.

7. Election of members to the Board of Directors.

The Board of Directors proposes re-election of all board members. The following board members are thus all running for re-election:

Lars Søren Rasmussen
Niels Peter Louis-Hansen
Annette Brøls
Carsten Hellmann
Jette Nygaard-Andersen
Marianne Wiinholt

A more detailed description of the candidates' special competencies and independence as well as management positions in other companies and demanding organisational tasks is provided in Annex 1 to this notice and is also available on the company's website, www.coloplast.com. The information is also available upon request to the company's Investor Relations department, tel. +45 4911 1800.

8. Election of auditors.

The Board of Directors proposes re-election of EY Godkendt Revisionspartnerselskab ("EY") as recommended by the Audit Committee. The election applies to statutory financial reporting as well as assurance engagements relating to sustainability reporting. The Audit Committee's recommendation has not been influenced by any third party and has not been subject to any agreement with any third party under which the election of certain auditors or audit firms by the shareholders would be restricted.

9. Authorisation to the chairman of the annual general meeting.

The Board of Directors proposes that the general meeting authorises the chairman of the general meeting, with full right of substitution, to apply for registration of the resolutions passed and to make any such amendments thereto that the Danish Business Authority or other authorities may require or recommend as a condition for registration or approval, as well as to make and apply for registration of linguistic and other non-substantive adjustments to the company's articles of association.

10. Any other business.

No other proposals have been tabled by the Board of Directors or by shareholders for consideration at the general meeting.

Majority requirement

The adoption of the proposed resolutions under agenda items 2, 3, 4, 5, 7, 8 and 9 requires a simple majority of votes pursuant to article 12 of the articles of association.

Shareholder information

The total share capital of the company amounts to DKK 228,200,000, of which DKK 18,000,000 are A-shares divided into shares of DKK 1 each or multiples thereof, and DKK 210,200,000 are B-shares divided into shares of DKK 1 each.

A shareholder's right to attend and vote at the general meeting is determined by the shares held by the shareholder on the record date, which is **Thursday, 28 November 2024**.

Each A-share of DKK 1 entitles the holder to ten votes, and each B-share of DKK 1 entitles the holder to one vote.

Any shareholder, attending the general meeting, may submit questions to the management at the general meeting. Questions regarding the agenda and other documents for the use of the general meeting may also be submitted in writing and is requested to be received by the company no later than one week prior to the date of the general meeting. Written questions must clearly identify the shareholder and be sent by email to

dkadim@coloplast.com and dkammi@coloplast.com or by ordinary mail to Coloplast A/S, Høltedam 1, 3050 Humlebæk, Denmark, marked "Investor Relations".

The following information will be available in the "Investor Relations" section on the company's website, www.coloplast.com, as of Tuesday, 12 November 2024:

- The notice convening the general meeting, including agenda and complete proposals.
- The total number of shares and voting rights as of the date when the general meeting is convened, including the total number for each share class.
- The annual report for 2023/24.
- The remuneration report for 2023/24.
- Forms to be used for voting by proxy and postal voting.

The notice convening the general meeting, including the complete proposals for consideration at the general meeting has, on 12 November 2024, also been sent to any shareholders registered in the shareholders register who has so requested. Furthermore, a registration form and a proxy and postal voting form are attached to the notice.

Payment of dividends

Dividends approved at the general meeting will be at the disposal of the shareholders on 10 December 2024, through the account-holding bank Nordea.

See page 5 of the 2023/24 Annual Report for additional information about dividends.

Admission cards

Admission cards will be issued to anyone who, according to the shareholders' register, is registered as a shareholder on the record date, Thursday 28 November 2024, or from whom the company has received due notice as of the record date for entry into the shareholders' register.

Any shareholder who has requested an admission card by **Monday, 2 December 2024, at 11.59 pm CET at the latest** is entitled to attend the general meeting. Shareholders who have issued a proxy or voted by postal vote may also attend the general meeting if they request an admission card within the deadline.

Admission cards for the general meeting may be requested:

- Online through the Shareholder Portal in the "Investor Relations" section on the company's website, www.coloplast.com. Requested admission cards will be sent by email to the email address registered in the Shareholder Portal when registering for the general meeting.

Or

- By sending a completed and signed registration form (that was attached to the notice) by email to gf@computershare.dk or by ordinary mail to Computershare A/S, Lottenborgvej 26, 2800 Kgs. Lyngby, Denmark. Shareholders may also use the registration form available in the "Investor Relations" section on the company's website, www.coloplast.com. **Please note the delivery time of the postal services if the registration form is sent by ordinary mail.** Admission cards requested using the registration form can be collected at the entrance to the general meeting upon presentation of valid photo ID.

Or

- By contacting Computershare A/S by telephone +45 4546 0997 (weekdays from 9:00 am to 3:00 pm CET).

Please note that admission cards will not be sent by ordinary mail. Shareholders who have registered for the general meeting in due time, i.e. by Monday 2 December 2024 at 11:59 pm CET at the latest, will be admitted to the general meeting upon presentation of the following at the entrance:

- An electronic admission card on a smartphone/tablet or a printout of the admission card if the shareholder has registered for the general meeting through the Shareholder Portal on the company's website.

Or

- Valid photo ID if the shareholder has registered for the general meeting by sending the registration form or by telephone.

Shareholders will receive a voting form at the entrance to the general meeting.

Shareholders who have submitted a proxy to the Chairman of the Board of Directors by use of the proxy form (attached to the notice) or submitted a postal vote may attend the general meeting if the shareholder registers for admission in due time by applying the registration form.

The shareholder or a proxy holder may attend the general meeting accompanied by an adviser.

For questions concerning registration for the general meeting or use of the Shareholder Portal, please contact Computershare A/S on tel. +45 4546 0997 (weekdays from 9:00 am to 3:00 pm CET).

Voting by proxy

Voting rights may be exercised through a proxy, who must present a written and dated power of attorney appointing the proxy. Such power of attorney cannot be issued for periods exceeding one year.

Proxies must be nominated by **Monday, 2 December 2024, 11:59 pm CET at the latest** either:

- Via the Shareholder Portal in the "Investor Relations" section on the company's website, www.coloplast.com.

Or

- By sending a completed and signed proxy and postal voting form (that was attached to the notice) by email to gf@computershare.dk or by ordinary mail to Computershare A/S, Lottenborgvej 26, 2800 Kgs. Lyngby, Denmark. Shareholders may also use the proxy and postal voting form available in the "Investor Relations" section on the company's website, www.coloplast.com. **Please note the delivery time of the postal services if the proxy form is sent by ordinary mail.**

Proxies may be revoked at any time.

Postal vote

Shareholders may vote by postal vote on the items on the agenda. Postal votes must be received by Computershare A/S on **Wednesday, 4 December 2024, at 9:00 am CET at the latest**. Postal votes may be cast either:

- Via the Shareholder Portal in the "Investor Relations" section on the company's website, www.coloplast.com.

Or

- By submitting a completed and signed proxy and postal voting form (that was attached to the notice) by email to gf@computershare.dk or by ordinary mail to Computershare A/S, Lottenborgvej 26, 2800 Kgs. Lyngby, Denmark. Shareholders may also use the proxy and postal voting form available in the "Investor Relations" section on the company's website, www.coloplast.com. **Please note the delivery time of the postal services if the postal voting form is sent by ordinary mail.**

Postal votes **cannot** be withdrawn.

Processing of personal data

The company processes personal data about its shareholders in compliance with the Danish Companies Act for the purposes of maintaining the company's shareholders register and sending convening notices and other communication. The following data is processed: names, addresses, contact details, securities account numbers, shareholdings and participation in events. You can read more about how Coloplast processes personal data on our website: https://www.coloplast.com/investor-relations/corporate-governance/data_privacy/.

Transport

The company will arrange bus transportation from Humlebæk train station to Coloplast and back to the station. Information about departure times is provided together with the attached driving directions.

The Board of Directors

Annex 1

Candidates for the Board of Directors

<p>Lars Rasmussen (65) Chairman 6 years on the Board, considered an independent Board member.</p> <p>Chairman of the Remuneration and Nomination Committee and member of the Audit Committee.</p> <p>Other board and management positions:</p> <ul style="list-style-type: none"> • H. Lundbeck A/S, (C) and chairman of the remuneration and nomination committee and member of the audit committee • Gyldendal A/S, (BM) • WS Audiology A/S, (C) • Mabtech AB, (C) • Danish Committee on Corporate Governance, (C) • University of Copenhagen, (BM) • Danish Life Science Council, (C) <p>Lars Rasmussen has extensive executive management and board experience from international listed companies in the med-tech and pharma industry. Lars Rasmussen possesses in-depth knowledge within commercialization of innovation, B2B and B2C sales models and efficiency improvements.</p>	<p>Niels Peter Louis-Hansen (77) Deputy Chairman 56 years on the Board, not considered an independent Board member.</p> <p>Member of the Remuneration and Nomination Committee.</p> <p>Other board and management positions:</p> <ul style="list-style-type: none"> • Aage og Johanne Louis-Hansens Fond, (C) • Aage og Johanne Louis-Hansen A/S, (C) • Coloplast Holding ApS, (C) • NPLH Holding ApS, CEO • N.P. Louis-Hansen ApS, CEO • NPLH Property Investments ApS, CEO • NPLH Anpartsinvest ApS, CEO <p>Through decades of board work, Niels Peter Louis-Hansen has gained in-depth knowledge of the industries in which Coloplast operates, its dynamics and key players as well as deep insight into strategy development. Furthermore, Niels Peter Louis-Hansen is a key contributor to preserving the Coloplast-culture.</p>
<p>Carsten Hellmann (60) 7 years on the Board, considered an independent Board member.</p> <p>Member of the Audit Committee.</p> <p>Other board and management positions:</p> <ul style="list-style-type: none"> • Chanelle Pharma, (C) • The Danish Chamber of Commerce, (BM) • Copenhagen Capacity, The Foundation for the Marketing of Business Promotion in the Capital Region, (BM) <p>Carsten Hellmann has considerable executive management experience. From 2016 to 2023, Carsten Hellmann was the President & CEO in ALK-Abelló A/S. Carsten Hellmann has extensive experience in product development and international commercialization within highly regulated industries as well as M&A activities, including post integration.</p>	<p>Jette Nygaard-Andersen (56) 9 years on the Board, considered an independent Board member.</p> <p>Member of the Remuneration and Nomination Committee.</p> <p>No other board and management positions.</p> <p>Jette Nygaard-Andersen has considerable executive management and board experience within global med-tech, media & entertainment, and digital growth businesses. She has extensive experience within business and marketing strategies, digital transformation, optimization of customer experience and engagement, working with digital growth start-ups globally and M&A activities, including post integration.</p>
<p>Marianne Wiinholt (59) 4 years on the Board, considered an independent Board member.</p> <p>Chairman of the Audit Committee.</p> <p>Other board and management positions:</p> <ul style="list-style-type: none"> • WS Audiology A/S, CFO • Widex A/S, (C) • Norsk Hydro ASA, (BM) and chairman of the audit committee <p>Marianne Wiinholt has considerable executive management experience. From April 2022, Marianne Wiinholt has acted as CFO in WS Audiology A/S which was formed in 2019 through the merger of Sivantos and Widex. Previously, Marianne Wiinholt acted as CFO in Ørsted A/S. Marianne Wiinholt has extensive experience within finance and accounting and considerable knowledge and experience in leading, driving and delivering a sustainability agenda on a global scale.</p>	<p>Annette Brüls (53) 3 years on the Board, considered an independent Board member.</p> <p>Member of the Remuneration and Nomination Committee.</p> <p>Other board and management positions:</p> <ul style="list-style-type: none"> • Edwards Lifesciences, Corporate Vice President, EMEACLA <p>Annette Brüls has considerable executive management experience within global medical device businesses. In 2024 she was appointed Corporate Vice President EMEACLA for Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Before that Annette Brüls was CEO of Medela AG. Annette Brüls has also spent 11 years with Medtronic holding several senior leadership positions in both Europe and the US. Annette Brüls has in-depth knowledge and understanding of product development and commercialization within the med-tech industry and in particular in chronic disease management, including digital services and value-based healthcare models.</p>

Bus transportation

In connection with the general meeting on Thursday, 5 December 2024, there will be busses driving approximately every 10 minutes from Humlebæk train station (country side) to Coloplast and return at the following times:

From Humlebæk Station to Coloplast:

2 pm until 3:30 pm

From Coloplast to Humlebæk Station:

At the end of the general meeting
approximately at 4:30 pm until 5.30 pm

The bus is parked in the square west of the railway at Humlebæk station (at Humlebæk Center).

Driving directions

By car from Copenhagen drive the E47 to Helsingør. Leave the motorway at exit 5 and turn right. At the first intersection turn right at Hørsholmvej.

The general meeting will be held in the auditorium at Hottedam 3, this is the second road on the right after the roundabout.



Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer.

Guided by empathy, our mission is to make life easier for people with intimate healthcare needs.

Over decades, we have helped millions of people live more independent lives and continue to do so through innovative products and services.

Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care.